HIV gp120 vaccine - VaxGen

Drug Profile

HIV gp120 vaccine - VaxGen

Alternative Names: AIDSVAX; AIDSVAX B/B'; AIDSVAX B/E; HIV gp120 vaccine - Genentech; HIV gp120 vaccine AIDSVAX - VaxGen; HIV vaccine AIDSVAX - VaxGen

Latest Information Update: 24 Oct 2013

Price : $50

At a glance

  • Originator Genentech; VaxGen
  • Developer VaxGen
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 24 Oct 2013 This programme is in active development with Global Solutions for Infectious Diseases
  • 29 May 2010 diaDexus to be acquired by VaxGen
  • 16 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top